CAR-T therapy could open door to kidney transplants for 'Incompatible' patients

NCT ID NCT07350837

Recruiting now Disease control Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

First seen Jan 21, 2026 · Last updated May 24, 2026 · Updated 21 times

Summary

This study tests a new treatment called AZD0120 (GC012F) in 12 adults with end-stage kidney disease who have high levels of antibodies that make it very hard to find a matching kidney donor. The treatment uses specially engineered immune cells (CAR-T) to target and reduce these antibodies, potentially allowing a successful kidney transplant. The main goals are to check safety and see if the therapy can lower antibody levels enough for transplantation.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGHLY SENSITIZED PATIENTS AWAITING KIDNEY TRANSPLANT are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Tongji Hospital, Tongji Medical Collage of Huazhong University of Science & Technology
RECRUITING

Wuhan, Hubei, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HIGHLY SENSITIZED PATIENTS AWAITING KIDNEY TRANSPLANT HIGHLY SENSITIZED PATIENTS AWAITING KIDNEY TRANSPLANT